Prudential Financial Inc. lowered its position in shares of Haemonetics Corporation (NYSE:HAE) by 3.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 100,322 shares of the medical instruments supplier’s stock after selling 3,090 shares during the period. Prudential Financial Inc.’s holdings in Haemonetics Corporation were worth $4,070,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. State of Alaska Department of Revenue increased its position in Haemonetics Corporation by 2.3% in the first quarter. State of Alaska Department of Revenue now owns 5,740 shares of the medical instruments supplier’s stock worth $232,000 after buying an additional 130 shares during the last quarter. Teachers Advisors LLC increased its position in Haemonetics Corporation by 2.5% in the fourth quarter. Teachers Advisors LLC now owns 85,025 shares of the medical instruments supplier’s stock worth $3,418,000 after buying an additional 2,081 shares during the last quarter. State Street Corp increased its position in Haemonetics Corporation by 8.0% in the fourth quarter. State Street Corp now owns 1,170,641 shares of the medical instruments supplier’s stock worth $47,057,000 after buying an additional 86,552 shares during the last quarter. Thrivent Financial for Lutherans increased its position in Haemonetics Corporation by 6.5% in the fourth quarter. Thrivent Financial for Lutherans now owns 27,780 shares of the medical instruments supplier’s stock worth $1,117,000 after buying an additional 1,690 shares during the last quarter. Finally, Swiss National Bank increased its position in Haemonetics Corporation by 1.4% in the first quarter. Swiss National Bank now owns 85,500 shares of the medical instruments supplier’s stock worth $3,469,000 after buying an additional 1,200 shares during the last quarter.
Shares of Haemonetics Corporation (HAE) opened at 39.31 on Monday. Haemonetics Corporation has a 52 week low of $28.15 and a 52 week high of $43.62. The stock has a 50 day moving average price of $41.41 and a 200-day moving average price of $40.15. The company’s market capitalization is $2.06 billion.
Haemonetics Corporation (NYSE:HAE) last posted its quarterly earnings data on Monday, May 8th. The medical instruments supplier reported $0.39 EPS for the quarter, topping the Zacks’ consensus estimate of $0.37 by $0.02. The company had revenue of $228.10 million for the quarter, compared to analyst estimates of $215.06 million. Haemonetics Corporation had a positive return on equity of 10.66% and a negative net margin of 2.96%. The firm’s quarterly revenue was down 5.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.37 earnings per share. Equities research analysts expect that Haemonetics Corporation will post $1.60 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Prudential Financial Inc. Sells 3,090 Shares of Haemonetics Corporation (HAE)” was first published by sleekmoney and is the sole property of of sleekmoney. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://sleekmoney.com/prudential-financial-inc-sells-3090-shares-of-haemonetics-corporation-hae/1939729.html.
A number of research analysts have issued reports on HAE shares. TheStreet downgraded shares of Haemonetics Corporation from a “b-” rating to a “c” rating in a research report on Monday, May 8th. Zacks Investment Research downgraded shares of Haemonetics Corporation from a “hold” rating to a “strong sell” rating in a research report on Tuesday, April 4th. Jefferies Group LLC restated a “buy” rating and set a $42.00 target price on shares of Haemonetics Corporation in a research report on Monday, May 8th. Finally, BidaskClub downgraded shares of Haemonetics Corporation from a “hold” rating to a “sell” rating in a research report on Friday. Three equities research analysts have rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the stock. Haemonetics Corporation currently has an average rating of “Hold” and an average target price of $35.83.
In related news, Director Ronald Merriman sold 17,471 shares of Haemonetics Corporation stock in a transaction that occurred on Monday, May 22nd. The stock was sold at an average price of $40.33, for a total value of $704,605.43. Following the transaction, the director now directly owns 24,925 shares of the company’s stock, valued at $1,005,225.25. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 1.20% of the stock is owned by insiders.
About Haemonetics Corporation
Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.
Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Corporation (NYSE:HAE).
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/prudential-financial-inc-sells-3090-shares-of-haemonetics-corporation-hae/1939729.html
Receive News & Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.